(Q34098608)

31 July 2017

1 reference

title

Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors (English)

1 reference

31 July 2017

A A Adjei

1

1 reference

31 July 2017

1 October 2000

1 reference

31 July 2017

1 reference

31 July 2017

11

1 reference

31 July 2017

10

1 reference

31 July 2017

1335-1341

1 reference

Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors

31 July 2017

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008379101017

7 January 2021

Polyglutamation of methotrexate. Is methotrexate a prodrug?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008379101017

7 January 2021

An update on thymidylate synthase inhibitors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008379101017

7 January 2021

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008379101017

7 January 2021

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008379101017

7 January 2021

Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008379101017

7 January 2021

Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008379101017

7 January 2021

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008379101017

7 January 2021

Folate status and the safety profile of antifolates

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008379101017

7 January 2021

Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008379101017

7 January 2021

Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008379101017

7 January 2021

The effect of a subnormal vitamin B-6 status on homocysteine metabolism

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008379101017

7 January 2021

Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008379101017

7 January 2021

Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008379101017

7 January 2021

Identifiers

DOI

10.1023/A:1008379101017

1 reference

31 July 2017

1 reference

PubMed ID

11106124